GlioblastomaBORDEAUX-GLIONCT07173829
A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression
An observational study of Glioblastoma, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma
- What is being tested?
- samples
- How many people
- 45 participants
- Where
- 1 siteFrance
- Study dates
- 22 Oct 2025to Oct 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
Who may be able to join
- Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
- Planned surgical tumor resection,
- No objection to participate in research
- Signed genetic consent
Who cannot join
- Patients under guardianship, curatorship or protective supervision
- Taking immunosuppressants
- Pregnant or breast-feeding women
- Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU de Bordeaux
Bordeaux
Julien ENGELHARDT, MD, 05 56 79 55 77 ext. +33, julien.engelhardt@chu-bordeaux.fr
About this study
Official title: A Prospective Study to Better Understand the Molecular, Immune and Metabolic Mechanisms Involved in Glioblastoma Recurrence and Progression, in the Aim to Identify New Therapeutic Targets and to Improve Current Therapies
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Read the detailed description
Glioblastoma is the most common and aggressive primary brain tumor in adults, whose relapse is almost systematic despite surgery, radiation therapy and temozolomide (STUPP protocol). Several clinical trials evaluating targeted therapy and immune checkpoint inhibitors have led to disappointed results. There is an unmet need to better understand the molecular and immune mechanisms underlying the invasion and progression of these tumors, in order to identify new therapeutic targets. The Bordeaux University Hospital is a leading French treatment center for glioblastoma, providing a large number of biological samples that can be analyzed at the molecular, immune and metabolic levels by specialized local teams.
Tumor tissue will be collected during patient surgery from primitive or recurrent glioblastoma, as well as blood samples, to perform transcriptomic and metabolomic analysis, including spatial transcriptomic and metabolomic, ex vivo generation of γδT lymphocytes and patient-derived xenografts.
A secondary objective is to develop, in preclinical models, innovative drugs with radiosensitizing effect and a γδT cell immunotherapy active against glioblastoma.
- Conditions
- Glioblastoma
- Being tested
- samples
- Keywords
- Glioblastoma progression, Glioblastoma recurrence, Metabolism, Lactate, Metabolomic, Transcriptomic, Radiation therapy, Radiosensitizer, Immunotherapy, γδ T lymphocytes
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
samplesOther
A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
| Study group | Role | What they receive |
|---|---|---|
| Recruited patient | Glioblastoma patient with indication for neurosurgery Receives: Other: samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Molecular mechanism
Description of the molecular mechanism involved in the progression and recurrence of glioblastoma
Measured: at inclusion (T0)
Metabolic mechanism
Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.
Measured: at inclusion (T0)
Immune mechanism
Description of the immune mechanism involved in the progression and recurrence of glioblastoma
Measured: at inclusion (T0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2025
- Study start22 Oct 2025
- Primary completionOct 2031 (estimated)
- Study completionOct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- More trials run by University Hospital, BordeauxThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Collaborators
- University of Bordeaux
- Responsible party
- Sponsor
- Investigators
- Julien ENGELHARDT, Dr, Principal investigator, University Hospital, BordeauxMathieu LARROQUETTE, Dr, Study chair, University Hospital, BordeauxGuillaume CHOTARD, Dr, Study chair, University Hospital, BordeauxLionel COUZI, Pr, Study chair, Bordeaux university Hospital, Bordeaux UniversityAndreas BIKFALVI, Pr, Study chair, University of BordeauxCharles DUPIN, Dr, Study chair, University Hospital, BordeauxVéronique VENDRELY, Pr, Study chair, Bordeaux university Hospital, Bordeaux UniversityJulie DECHANET-MERVILLE, Dr, Study chair, University of Bordeaux
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07173829
- Sponsor's protocol ID
- CHUBX 2023/06
- Acronym
- BORDEAUX-GLIO
- Status last verified
- Aug 2026
- First submitted
- 2 Aug 2023
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study to Better Understand the Molecular, Immune and Metabolic Mechanisms Involved in Glioblastoma Recurrence and Progression, in the Aim to Identify New Therapeutic Targets and to Improve Current Therapies
- ClinicalTrials.gov ID
- NCT07173829
- Acronym / sponsor ID
- BORDEAUX-GLIO / CHUBX 2023/06
- Conditions
- Glioblastoma
- Keywords
- Glioblastoma progression, Glioblastoma recurrence, Metabolism, Lactate, Metabolomic, Transcriptomic, Radiation therapy, Radiosensitizer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Collaborators
- University of Bordeaux
- Study start
- 22 Oct 2025 (actual)
- Primary completion
- Oct 2031 (estimated)
- Study completion
- Oct 2031 (estimated)
- First posted
- 15 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Detailed description
Glioblastoma is the most common and aggressive primary brain tumor in adults, whose relapse is almost systematic despite surgery, radiation therapy and temozolomide (STUPP protocol). Several clinical trials evaluating targeted therapy and immune checkpoint inhibitors have led to disappointed results. There is an unmet need to better understand the molecular and immune mechanisms underlying the invasion and progression of these tumors, in order to identify new therapeutic targets. The Bordeaux University Hospital is a leading French treatment center for glioblastoma, providing a large number of biological samples that can be analyzed at the molecular, immune and metabolic levels by specialized local teams.
Tumor tissue will be collected during patient surgery from primitive or recurrent glioblastoma, as well as blood samples, to perform transcriptomic and metabolomic analysis, including spatial transcriptomic and metabolomic, ex vivo generation of γδT lymphocytes and patient-derived xenografts.
A secondary objective is to develop, in preclinical models, innovative drugs with radiosensitizing effect and a γδT cell immunotherapy active against glioblastoma.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Recruited patient | – | Other: samplesGlioblastoma patient with indication for neurosurgery |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
Key inclusion criteria (4 listed)
- Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
- Planned surgical tumor resection,
- No objection to participate in research
- Signed genetic consent
Key exclusion criteria (4 listed)
- Patients under guardianship, curatorship or protective supervision
- Taking immunosuppressants
- Pregnant or breast-feeding women
- Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| samplesA 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor. | Other | Recruited patient |
Primary outcome
Molecular mechanism
Time frame: at inclusion (T0)
Description of the molecular mechanism involved in the progression and recurrence of glioblastoma
Metabolic mechanism
Time frame: at inclusion (T0)
Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.
Immune mechanism
Time frame: at inclusion (T0)
Description of the immune mechanism involved in the progression and recurrence of glioblastoma
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Julien ENGELHARDT, Dr principal investigator
University Hospital, Bordeaux
Mathieu LARROQUETTE, Dr study chair
University Hospital, Bordeaux
Guillaume CHOTARD, Dr study chair
University Hospital, Bordeaux
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioblastoma, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Julien ENGELHARDT, Dr (05 56 79 55 77 ext. +33, julien.engelhardt@chu-bordeaux.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Molecular mechanism (time frame: at inclusion (T0)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.